1. Home
  2. CFND vs ANVS Comparison

CFND vs ANVS Comparison

Compare CFND & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CFND

C1 Fund Inc.

N/A

Current Price

$4.04

Market Cap

27.4M

Sector

N/A

ML Signal

N/A

Logo Annovis Bio Inc.

ANVS

Annovis Bio Inc.

N/A

Current Price

$2.49

Market Cap

111.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CFND
ANVS
Founded
N/A
2008
Country
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.4M
111.3M
IPO Year
2025
2019

Fundamental Metrics

Financial Performance
Metric
CFND
ANVS
Price
$4.04
$2.49
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$13.50
AVG Volume (30 Days)
24.3K
306.4K
Earning Date
N/A
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
62.92
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.68
$1.11
52 Week High
$9.67
$5.50

Technical Indicators

Market Signals
Indicator
CFND
ANVS
Relative Strength Index (RSI) 45.00 43.60
Support Level $3.75 $2.27
Resistance Level $4.08 $2.63
Average True Range (ATR) 0.17 0.20
MACD 0.04 0.02
Stochastic Oscillator 58.00 21.54

Price Performance

Historical Comparison
CFND
ANVS

About CFND C1 Fund Inc.

C1 Fund Inc is a non-diversified, closed-end management investment company designed to give investors access to the private digital asset ecosystem. Its investment objective is to maximize its portfolio's total return. The fund targets a handpicked portfolio of the late-stage private companies driving the future of digital asset services and technology. It offers early access to the next generation of category-defining companies and aims to bridge the gap between public and private markets and give investors access to the private companies with the safeguards of a NYSE listed fund that is regulated and liquid.

About ANVS Annovis Bio Inc.

Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.

Share on Social Networks: